Why do non-smokers get lung cancer?
“(NEXSTAR) – Last month, actress and comedian Kate Micucci revealed that she had been diagnosed and treated for lung cancer despite “never” having smoked a cigarette in her life. “It was a surprise, but also, I guess it happens,” the “Big Bang Theory” actress said, shortly before confirming she had undergone treatment and is now “cancer-free.”

Breakthrough research identifies predictors of venous thromboembolism after pulmonary resection for lung cancer
“A new study presented at The Society of Thoracic Surgeons’ 2024 Annual Meeting in San Antonio, Texas, examines the ongoing controversy surrounding the choice between multi-arterial grafting (MAG) and single arterial grafting (SAG) in coronary artery bypass grafting (CABG) for multivessel coronary revascularization.”

Safety and efficacy of immune checkpoint inhibitor rechallenge in advanced non-small cell lung cancer: a retrospective study
“We conducted a retrospective study to evaluate the efficacy of immune checkpoint inhibitor (ICI) rechallenge in patients with advanced non-small cell lung cancer (NSCLC). The study included 111 patients who had previously received ICI therapy and experienced disease progression. The primary endpoints assessed were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Our findings revealed that the ICI rechallenge showed promising results in improving patient outcomes. OS (r) is the time from rechallenging with immune checkpoint inhibitors to the last follow-up or death from any cause.”

FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2-Positive Solid Tumors
“The FDA has granted priority review to a supplemental biologics license application (sBLA) seeking the approval of the HER2-directed antibody-drug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment or for whom no satisfactory treatment alternatives exist.”

Mirtazapine improves caloric intake compared to placebo in patients with advanced non-small cell lung cancer
“1. While perceived appetite did not differ between study groups, patients receiving mirtazapine had significantly increased caloric consumption compared with the placebo group.

  1. Mirtazapine is well-tolerated, with nightmares being one of the primary significant adverse events, but the difference was insignificant at both the 4- and 8-week follow-up points.”

Study identifies risk factors for deadly blood clots after lung cancer surgery
“In patients who undergo pulmonary resection for lung cancer, a major potential postoperative complication is venous thromboembolism (VTE)-;a condition that develops when a blood clot forms in a vein-;which can lead to part of the clot breaking off and lodging in the lung, resulting in a pulmonary embolism (PE).”

Is lung cancer treatment working? This chip can tell from a blood draw
“By trapping and concentrating tiny numbers of cancer cells from blood samples, the device can identify whether a treatment is effective at the four-week mark”

“A new study says Oklahoma ranks 40th in the country for the number of people who survive lung cancer. Doctors have recently changed the guidelines for who can get screened for lung cancer, but in Oklahoma, only 1.7% of people who are eligible to get screened actually do.”

Response score-based protein structure analysis for cancer prediction aided by the Internet of Things
“Medical diagnosis through prediction and analysis is par excellence in integrating modern technologies such as the Internet of Things (IoT). With the aid of such technologies, clinical assessments are eased with protracted computing. Specifically, cancer research through structure prediction and analysis is improved through human and machine interventions sustaining precision improvements. This article, therefore, introduces a Protein Structure Prediction Technique based on Three-Dimensional Sequence. This sequence is modeled using amino acids and their folds observed during the pre-initial cancer stages.”

How genomic testing is reshaping the way we find and treat cancer
“Cancer is a disease of the genome. In cancer, diagnoses are done largely by looking through the microscope at the appearance of cancer cells and, often, the organ the cancer comes from offers the most important way of making the diagnosis. But, over the past couple of decades, doctors and researchers have realised that a much better way to diagnose cancer is by the molecular abnormalities that distinguish cancer cells from normal ones; these abnormalities are often changes in the DNA sequence in the genome of the cancer cells.”

KRAS Mutation in NSCLC Linked to Female Sex, Presence of CNS Metastasis
“The treatment armamentarium for non-small cell lung cancer (NSCLC) is evolving, with increased focus on biomarkers for individualized treatment decisions. Current diagnostic guidelines include treatment-predictive molecular testing for several oncogenic drivers for targeted therapy. Adenocarcinoma and squamous cell carcinoma (SCC) are the two largest histologic subgroups of NSCLC and are genetically different regarding patterns of acquired oncogenic mutations.”

Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial
“Conclusions: The frequency, distribution and clustering of immune cells relative to malignant ones can impact ICI efficacy in SqNSCLC patients. High CNV burden may contribute to the cold immune microenvironment. Soluble inflammation/immune-related proteins in the blood have the potential to monitor therapeutic benefit from ICI treatment in SqNSCLC patients.”

Treatment Duration With ICIs Impacts Prognosis in Patients With NSCLC
“Immune checkpoint inhibitor (ICI) ± chemotherapy has been shown to prolong survival in patients with advanced non-small cell lung cancer (NSCLC). Some recent sponsor-initiated clinical trials used a fixed 24-month duration or continuous treatment until documented disease progression for investigational ICIs. Additionally, an exploratory analysis of CheckMate 153, which evaluated the impact of continuous versus 1-year fixed-duration ICI treatment protocol in previously treated patients with advanced NSCLC, showed that the continuous use of ICI beyond 1 year improves prognosis.”

FDA grants 510(k) clearance to AI-based lung segmentation software
“The FDA has granted 510(k) clearance to LungQ 3.0.0, an artificial intelligence-based software that identifies different parts of lung anatomy and evaluates lung tissue and fissure completeness, according to a press release. With use of this version of LungQ (Thirona), the release said physicians will feel supported when diagnosing and documenting pulmonary tissue images since the software identifies and separates pulmonary segments and subsegments.”

Survey of US oncologists highlights advanced lung cancer research gaps
“A new survey commissioned by the Cancer Research Institute (CRI) and Regeneron Pharmaceuticals has highlighted that more research is needed to improve treatment for advanced non-small cell lung cancer (NSCLC). Responsible for around 85% of all lung cancers, NSCLC is any type of epithelial lung cancer other than small cell lung cancer.”